share_log

Allgens Medical Technology (SHSE:688613) Posted Weak Earnings But There Is More To Worry About

Allgens Medical Technology (SHSE:688613) Posted Weak Earnings But There Is More To Worry About

Allgens Medical Technology(上海證券交易所代碼:688613)公佈了疲軟的收益,但還有更多值得擔心的地方
Simply Wall St ·  05/02 18:56

The market shrugged off Allgens Medical Technology CO., LTD.'s (SHSE:688613) weak earnings report. Despite the market responding positively, we think that there are several concerning factors that investors should be aware of.

市場對Allgens Medical Technology CO., LTD不屑一顧。”s(上海證券交易所代碼:688613)疲軟的收益報告。儘管市場反應積極,但我們認爲投資者應注意一些令人擔憂的因素。

earnings-and-revenue-history
SHSE:688613 Earnings and Revenue History May 2nd 2024
SHSE: 688613 收益和收入歷史記錄 2024 年 5 月 2 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

For anyone who wants to understand Allgens Medical Technology's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥15m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Allgens Medical Technology had a rather significant contribution from unusual items relative to its profit to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

對於任何想了解Allgens Medical Technology在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值1500萬元人民幣的不尋常物品中獲得了法定利潤。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。相對於其截至2024年3月的利潤,Allgens Medical Technology的不尋常項目做出了相當大的貢獻。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Allgens Medical Technology.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對Allgens Medical Technology的資產負債表分析。

An Unusual Tax Situation

不尋常的稅收狀況

Having already discussed the impact of the unusual items, we should also note that Allgens Medical Technology received a tax benefit of CN¥6.0m. This is meaningful because companies usually pay tax rather than receive tax benefits. The receipt of a tax benefit is obviously a good thing, on its own. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. In the likely event the tax benefit is not repeated, we'd expect to see its statutory profit levels drop, at least in the absence of strong growth.

在已經討論了這些不尋常物品的影響之後,我們還應該指出,Allgens Medical Technology獲得了600萬元人民幣的稅收優惠。這是有意義的,因爲公司通常納稅而不是獲得稅收優惠。獲得稅收優惠本身顯然是一件好事。但是,細節上的問題在於,此類福利僅在預訂當年有影響,而且本質上通常是一次性的。如果稅收優惠可能不重演,我們預計其法定利潤水平將下降,至少在沒有強勁增長的情況下是如此。

Our Take On Allgens Medical Technology's Profit Performance

我們對Allgens醫療科技盈利表現的看法

In its last report Allgens Medical Technology received a tax benefit which might make its profit look better than it really is on a underlying level. Furthermore, it also benefitted from a positive unusual item, which boosted the profit result even higher. Considering all this we'd argue Allgens Medical Technology's profits probably give an overly generous impression of its sustainable level of profitability. If you want to do dive deeper into Allgens Medical Technology, you'd also look into what risks it is currently facing. For example, Allgens Medical Technology has 4 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

在上一份報告中,Allgens Medical Technology獲得了稅收優惠,這可能會使其利潤看起來比實際水平要好。此外,它還受益於一個積極的不尋常項目,這進一步提高了利潤結果。考慮到所有這些,我們認爲Allgens Medical Technology的利潤可能給人一種對其可持續盈利水平的過於慷慨的印象。如果你想更深入地研究Allgens Medical Technology,你還需要研究它目前面臨的風險。例如,Allgens Medical Technology 有 4 個警告信號(其中一個不太適合我們),我們認爲你應該知道。

In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

在這篇文章中,我們研究了許多可能損害利潤數字效用的因素,我們採取了謹慎的態度。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論